This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
News|Articles|July 2, 2019
Pfizer Completes Acquisition of Clinical-Stage Biotech
Author(s)Pharmaceutical Technology Editors
Pfizer has successfully completed its acquisition of Therachon, a privately held clinical-stage biotechnology company.
Advertisement
Pfizer has successfully completed its acquisition of Therachon, a privately held clinical-stage biotechnology company, it was announced in a July 1, 2019 press release.
The acquisition was completed for US$340 million with an additional US$470 million in supplementary payments. The additional payments are dependent on key milestones being achieved in the development and commercialization of an investigational medicine for the treatment of achondroplasia, TA-46.
“Therachon becoming part of Pfizer is representative of our Rare Disease team’s 30-year commitment to develop innovative medicines that address significant unmet medical needs of people with rare diseases,” said Seng Cheng, senior vice-president and chief scientific officer of Pfizer’s Rare Disease Research Unit, in a press release. “With our leading scientific and development capabilities, we believe we can effectively advance the development of TA-46, which has the potential to be a first-in-class therapy for the treatment of achondroplasia.”
Source:
Advertisement
Related to this article
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Advertisement
Advertisement